November 25, 2019
AbbVie made inroads into the Japanese oncology market with the launch of its first cancer drug Venclexta (venetoclax) for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Venclexta is the first drug in a class of oral medicines called...read more